Outreach and Connection to Care for Chronic Kidney Disease in a Workplace Wellness Setting: A Cost-Effectiveness Analysis

被引:0
作者
Li, Yonghong [1 ]
Devlin, James J. [1 ]
机构
[1] Quest Diagnost, 33608 Ortega Highway, San Juan Capistrano, CA 92675 USA
关键词
chronic kidney disease; cost-effectiveness analysis; Markov modeling; CARDIOVASCULAR OUTCOMES; NEPHROPATHY; INHIBITORS;
D O I
10.1089/pop.2019.0206
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Because chronic kidney disease (CKD) is underdiagnosed, many patients do not receive care that could slow or prevent progression. Potential CKD patients can be identified during employee wellness events and referred into care by a CKD outreach program. This study assessed the health and economic benefits associated with a CKD outreach program. A model-based cost-effectiveness analysis was conducted for a cohort of patients at risk for CKD under 2 scenarios: wellness events with a CKD outreach program and wellness events without outreach. The outreach program identified potential CKD patients based on estimated glomerular filtration rates. Health outcomes and total cost to payers were estimated with Markov models using 1-year cycles. Because outreach could be offered to either patients with diabetes or to all potential CKD patients, these groups were modeled separately. The authors assumed 40% percent of potential CKD patients accepted the invitation to participate in the CKD outreach program. Model parameters were taken from peer-reviewed literature. The study was conducted from the perspective of self-insured employers over a 5-year time horizon. The study found that the CKD outreach program resulted in a gain of 2.3 quality-adjusted life-years and saved $500,211 when 1000 potential CKD patients with diabetes were invited. When potential CKD patients were invited without regard for diabetes status, 0.8 quality-adjusted life-years were gained at a cost savings of $34,161. The authors concluded that CKD outreach programs can improve health outcomes for patients with CKD and save costs for payers.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 21 条
  • [1] Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands - A Markov Model
    Adarkwah, Charles Christian
    Gandjour, Afschin
    Akkerman, Maren
    Evers, Silvia M.
    [J]. PLOS ONE, 2011, 6 (10):
  • [2] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
    Adler, AI
    Stevens, RJ
    Manley, SE
    Bilous, RW
    Cull, CA
    Holman, RR
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (01) : 225 - 232
  • [3] [Anonymous], 2016, 2016 USRDS Annual Data Report: Epidemiology of kidney disease in the United States
  • [4] [Anonymous], 2017, National Chronic Kidney Disease Fact Sheet
  • [5] Screening for proteinuria in US adults - A cost-effectiveness analysis
    Boulware, LE
    Jaar, BG
    Tarver-Carr, ME
    Brancati, FL
    Powe, NR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (23): : 3101 - 3114
  • [6] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [7] The Costs and Benefits of Automatic Estimated Glomerular Filtration Rate Reporting
    den Hartog, Julia R.
    Reese, Peter P.
    Cizman, Borut
    Feldman, Harold I.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02): : 419 - 427
  • [8] Albuminuria and renal insufficiency prevalence guides population screening: Results from the NHANES III
    Garg, AX
    Kiberd, BA
    Clark, WF
    Haynes, RB
    Clase, CM
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (06) : 2165 - 2175
  • [9] Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    Go, AS
    Chertow, GM
    Fan, DJ
    McCulloch, CE
    Hsu, CY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) : 1296 - 1305
  • [10] Golestaneh L, 2017, AM J MANAG CARE, V23, pS163